ONC206 is a recently discovered compound that may stop cancer cells from growing. This small-molecule drug is administered orally, and has been shown in laboratory experiments to kill brain tumor cells by causing a "stress response" in tumor cells. This stress response causes cancer cells to die, but without affecting normal cells.

2021年10月22日 · Brett Theeler, M.D., neurologist and neuro-oncologist in the United States Army Medical Corps and clinical collaborator at the NCI Center for Cancer Research's Neuro-Oncology Branch, is taking a hopeful step forward to treat recurrent CNS cancers in a new first-in-human trial with ONC206, an oral, targeted cancer therapy. The trial tests the ...

ONC206 is a recently discovered compound that may stop cancer cells from growing. This drug has been shown in laboratory experiments to kill brain tumor cells by causing a so called "stress response" in tumor cells. This stress response causes …

ONC206 is a dual targeted investigational therapy that is an agonist of the mitochondrial protease ClpP and an antagonist of the G protein-coupled receptor DRD2. As a small molecule derivative of dordaviprone, ONC206 exhibits enhanced nanomolar potency while retaining safety, oral administration, and CNS penetration attributes.

2024年12月6日 · This phase I trial studies the effects and best dose of ONC206 alone or in combination with radiation therapy in treating patients with diffuse midline gliomas that is newly diagnosed or has come back (recurrent) or other recurrent primary malignant CNS tumors. ONC206 is a recently discovered compound that may stop cancer cells from growing.

ONC206 is a small molecule imipridone that antagonizes the G protein-coupled receptors (GPCRs), dopamine receptor D2 (DRD2) and D3 (DRD3). Downstream of target engagement in tumor cells, ONC206 causes activation of the integrated stress response (ISR), inactivation of pro- survival Akt and ERK signaling, and induction of the DR5/TRAIL pathway.

2023年4月23日 · ONC201 and ONC206 reduced mitochondrial oxidative phosphorylation, oxygen consumption rate, and ATP production. In addition, both drugs were found to trigger apoptosis and the integrated stress response (ISR), with the latter evident in vivo in the subcutaneous setting as well as in vitro.

2020年11月9日 · Promising preclinical and clinical results have been obtained for adult and pediatric malignant glioma treated with ONC-201, a selective antagonist of DRD2, a G-protein coupled receptor that regulates prosurvival pathways. Herein, we report the activity of ONC-201 and ONC-206, which has increased non-competitive antagonism of DRD2, against MB.

2024年1月8日 · 近日，脑胶质瘤小分子口服创新药物ONC201和ONC206正式更名，新名称为Imipridon-201、Imipridon-206，这意味着这款新型靶向药物正在更快、更便捷地为全世界所共享，让极为难治的脑胶质瘤患者群体看到了希望！

ONC-206是由Oncoceutics Inc研发的一种小分子药物，是一种DRD2拮抗剂。